{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:17:47Z","timestamp":1771877867726,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11523-017-0522-5","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T01:08:19Z","timestamp":1501722499000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Giovan Giuseppe","family":"Di Costanzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casadei Gardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Marisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Faloppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Ostilio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Ercolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"522_CR1","doi-asserted-by":"crossref","unstructured":"Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359\u201386.","DOI":"10.1002\/ijc.29210"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cld.2004.12.009","volume":"9","author":"FX Bosch","year":"2005","unstructured":"Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191\u2013211.","journal-title":"Clin Liver Dis"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bpg.2015.09.007","volume":"29","author":"GB Goh","year":"2015","unstructured":"Goh GB, Chang P, Tan C. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919\u201328.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"522_CR4","doi-asserted-by":"crossref","unstructured":"Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140\u201351.","DOI":"10.1016\/j.cgh.2015.08.014"},{"key":"522_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL\u2013EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"522_CR6","doi-asserted-by":"crossref","unstructured":"Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An update. Hepatology. 2011;53:1020\u20132.","DOI":"10.1002\/hep.24199"},{"key":"522_CR7","doi-asserted-by":"crossref","unstructured":"Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the liver consensus. Hepatol Int. 2010;4:439\u201374.","DOI":"10.1007\/s12072-010-9165-7"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1159\/000439102","volume":"33","author":"N Nishida","year":"2015","unstructured":"Nishida N, Kitano M, Sakurai T, et al. Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. Dig Dis. 2015;33:771\u20139.","journal-title":"Dig Dis"},{"key":"522_CR9","first-page":"428","volume":"7","author":"M Berretta","year":"2016","unstructured":"Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. 2016;7:428.","journal-title":"Front Pharmacol"},{"key":"522_CR10","doi-asserted-by":"crossref","unstructured":"Cao G, Li X, Qin C, Li J. Prognostic value of VEGF in hepatocellular carcinoma patients treated with Sorafenib: A meta-analysis. Med Sci Monit. 2015;21:3144\u201351.","DOI":"10.12659\/MSM.894617"},{"key":"522_CR11","doi-asserted-by":"crossref","unstructured":"Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","DOI":"10.1016\/j.jhep.2012.06.014"},{"key":"522_CR12","doi-asserted-by":"crossref","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"522_CR13","doi-asserted-by":"crossref","unstructured":"Lencioni R, Kudo M, Ye SL, et al. GIDEON (global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): Second interim analysis. Int J Clin Pract. 2014;68:609\u201317.","DOI":"10.1111\/ijcp.12352"},{"key":"522_CR14","doi-asserted-by":"crossref","unstructured":"Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2013Pacific trial. Eur J Cancer. 2012;48:1452\u201365.","DOI":"10.1016\/j.ejca.2011.12.006"},{"key":"522_CR15","doi-asserted-by":"crossref","unstructured":"Song T, Zhang W, Wu Q, et al. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: Evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233\u20138.","DOI":"10.1097\/MEG.0b013e32834bd2d0"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/j.1365-2036.2011.04823.x","volume":"34","author":"M Pinter","year":"2011","unstructured":"Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011;34:949\u201359.","journal-title":"Aliment Pharmacol Ther"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.dld.2012.10.010","volume":"45","author":"MA W\u00f6rns","year":"2013","unstructured":"W\u00f6rns MA, Koch S, Niederle IM, et al. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45:408\u201313.","journal-title":"Dig Liver Dis"},{"key":"522_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/liv.12168","volume":"33","author":"JY Cho","year":"2013","unstructured":"Cho JY, Paik YH, Lim HY, et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33:950\u20137.","journal-title":"Liver Int"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","volume":"18","author":"JM Llovet","year":"2012","unstructured":"Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290\u2013300.","journal-title":"Clin Cancer Res"},{"key":"522_CR20","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhou X, Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 2009;7:41.","DOI":"10.1186\/1741-7015-7-41"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","volume":"15","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85\u201392.","journal-title":"Oncologist"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/bjc.2011.507","volume":"105","author":"F Di Fiore","year":"2011","unstructured":"Di Fiore F, Rigal O, M\u00e9nager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 2011;105:1811\u20133.","journal-title":"Br J Cancer"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/fon.14.291","volume":"11","author":"GG Di Costanzo","year":"2015","unstructured":"Di Costanzo GG, De Stefano G, Tortora R, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11:943\u201351.","journal-title":"Future Oncol"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"522_CR25","doi-asserted-by":"crossref","unstructured":"Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: A systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458\u201366.","DOI":"10.1016\/S1499-3872(12)60209-4"},{"key":"522_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.7314\/APJCP.2013.14.2.691","volume":"14","author":"Z Wang","year":"2013","unstructured":"Wang Z, Wu XL, Zeng WZ, Xu GS, Xu H, et al. Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:691\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"key":"522_CR27","doi-asserted-by":"publisher","first-page":"e112530","DOI":"10.1371\/journal.pone.0112530","volume":"9","author":"S Peng","year":"2014","unstructured":"Peng S, Zhao Y, Xu F, Jia C, Xu Y, et al. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530.","journal-title":"PLoS One"},{"key":"522_CR28","doi-asserted-by":"crossref","unstructured":"Shao YY, Shau WY, Chan SY, Lu LC, Hsu CH, Cheng AL. Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials. Oncology. 2015;88:345\u201352.","DOI":"10.1159\/000369559"},{"key":"522_CR29","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-15-2883","volume":"22","author":"AX Zhu","year":"2016","unstructured":"Zhu AX, Kang YK, Rosmorduc O, Evans TJ, Santoro A, Ross P, et al. Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial. Clin Cancer Res. 2016;22:4870\u20139.","journal-title":"Clin Cancer Res"},{"key":"522_CR30","doi-asserted-by":"crossref","unstructured":"Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Japanese Red Cross Liver Study Group, et al. Proposal of Japan red cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res. 2015;45(10):E130\u201340.","DOI":"10.1111\/hepr.12480"},{"key":"522_CR31","doi-asserted-by":"crossref","unstructured":"Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008;47:176\u201386.","DOI":"10.1080\/02841860701765675"},{"key":"522_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","volume":"36","author":"L Zhang","year":"2011","unstructured":"Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36:344\u201350.","journal-title":"Clin Exp Dermatol"},{"key":"522_CR33","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.3748\/wjg.v20.i35.12581","volume":"20","author":"M Yada","year":"2014","unstructured":"Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20:12581\u20137.","journal-title":"World J Gastroenterol"},{"key":"522_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4254\/wjh.v6.i9.670","volume":"6","author":"M Shomura","year":"2014","unstructured":"Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6:670\u20136.","journal-title":"World J Hepatol"},{"key":"522_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","volume":"42","author":"T Otsuka","year":"2012","unstructured":"Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42:879\u201386.","journal-title":"Hepatol Res"},{"key":"522_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","volume":"61","author":"M Reig","year":"2014","unstructured":"Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318\u201324.","journal-title":"J Hepatol"},{"key":"522_CR37","doi-asserted-by":"crossref","unstructured":"Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, et al. Incidence and risk of sorafenib-induced hypertension: A systematic review and meta-analysis. J Clin Hypertens. 2014;16:177\u201385.","DOI":"10.1111\/jch.12273"},{"key":"522_CR38","doi-asserted-by":"crossref","unstructured":"Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: An updated systematic review and meta-analysis. J Hum Hypertens. 2013;27:601\u201311.","DOI":"10.1038\/jhh.2013.30"},{"key":"522_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"O Hamnvik","year":"2015","unstructured":"Hamnvik O, Choueiri T, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311\u20139.","journal-title":"Cancer"},{"key":"522_CR40","doi-asserted-by":"crossref","unstructured":"Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319\u201324.","DOI":"10.1097\/COC.0b013e3182468039"},{"key":"522_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10147-014-0691-5","volume":"20","author":"N Akutsu","year":"2015","unstructured":"Akutsu N, Sasaki S, Takagi H, et al. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol. 2015;20:105\u201310.","journal-title":"Int J Clin Oncol"},{"key":"522_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"522_CR43","doi-asserted-by":"crossref","unstructured":"Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol. 2006;24:1329\u201331.","DOI":"10.1200\/JCO.2005.04.5740"},{"key":"522_CR44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/annonc\/mdp018","volume":"20","author":"BI Levy","year":"2009","unstructured":"Levy BI. Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor. Ann Oncol. 2009;20:200\u20133.","journal-title":"Ann Oncol"},{"key":"522_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227\u201330.","journal-title":"Ann Oncol"},{"key":"522_CR46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","volume":"26","author":"CM Rudin","year":"2008","unstructured":"Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008;26:1119\u201327.","journal-title":"J Clin Oncol"},{"key":"522_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000342425","volume":"84","author":"R Koschny","year":"2013","unstructured":"Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013;84:6\u201313.","journal-title":"Oncology"},{"key":"522_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/hep.25637","volume":"56","author":"D Bettinger","year":"2012","unstructured":"Bettinger D, Schulthei\u00df M, Knuppel E, et al. Diarrhoea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56:789.","journal-title":"Hepatology"},{"key":"522_CR49","doi-asserted-by":"crossref","unstructured":"Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: A multi-centre real-world study. Scand J Gastroenterol. 2016;51:979\u201385.","DOI":"10.3109\/00365521.2016.1166518"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-017-0522-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0522-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0522-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:17:09Z","timestamp":1659086229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-017-0522-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1007\/s11523-017-0522-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]},"assertion":[{"value":"3 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}